Abstract

Alzheimer’s disease (AD) is a neurodegenerative condition, of which one of the cardinal pathological hallmarks is the extracellular accumulation of amyloid β (Aβ) peptides. These peptides are generated via proteolysis of the amyloid precursor protein (APP), in a manner dependent on the β-secretase, BACE1 and the multicomponent γ-secretase complex. Recent data also suggest a contributory role in AD of transactive response DNA binding protein 43 (TDP-43). There is little insight into a possible mechanism linking TDP-43 and APP processing. To this end, we used cultured human neuronal cells to investigate the ability of TDP-43 to interact with APP and modulate its proteolytic processing. Immunocytochemistry showed TDP-43 to be spatially segregated from both the extranuclear APP holoprotein and its nuclear C-terminal fragment. The latter (APP intracellular domain) was shown to predominantly localise to nucleoli, from which TDP-43 was excluded. Furthermore, neither overexpression of each of the APP isoforms nor siRNA-mediated knockdown of APP had any effect on TDP-43 expression. Doxycycline-stimulated overexpression of TDP-43 was explored in an inducible cell line. Overexpression of TDP-43 had no effect on expression of the APP holoprotein, nor any of the key proteins involved in its proteolysis. Furthermore, increased TDP-43 expression had no effect on BACE1 enzymatic activity or immunoreactivity of Aβ1-40, Aβ1-42 or the Aβ1-40:Aβ1-42 ratio. Also, siRNA-mediated knockdown of TDP-43 had no effect on BACE1 immunoreactivity. Taken together, these data indicate that TDP-43 function and/or dysfunction in AD is likely independent from dysregulation of APP expression and proteolytic processing and Aβ generation.

Highlights

  • Alzheimer’s disease (AD) is a progressive neurodegenerative disease and the most common form of dementia [1]

  • Given a previous report linking transactive response DNA binding protein 43 (TDP-43) to β-site APP cleaving enzyme 1 (BACE1) [41], we further focused on these proteins

  • We have focused on the interaction of TDP-43 with amyloid precursor protein (APP) proteolytic processing

Read more

Summary

Introduction

Alzheimer’s disease (AD) is a progressive neurodegenerative disease and the most common form of dementia [1] It is traditionally characterised by a bipartite pathology featuring plaques comprising amyloid β (Aβ) peptide and neurofibrillary tangles containing the microtubule-associated protein τ [1,2]. Amyloidogenic processing is the minor pathway and involves sequential cleavage by β-secretase, BACE1 and the γ-secretase complex (comprising presenilin 1 or 2, nicastrin, Aph and Pen2) [6–8]. This releases Aβ species (Aβ1-40 and Aβ1-42 are the most significant), which may play a role in the pathogenesis of AD [9]. The second, non-amyloidogenic, pathway involves α-secretase cleavage of APP, a function ascribed to the metalloprotease ADAM10 in neurons [10].

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.